جستجوی استاد راهنمای دانشگاهی

Hutan Ashrafianمشاهده پروفایل

استاد

• Artificial Intelligence in Medicine
• Metabolic Surgery
• Health Policy
• +۴ مورد دیگر

Professor Hutan Ashrafian is a clinician-scientist and surgeon at the University of Leeds Business School, holding dual roles as Professor of Research Impact and Senior Research Fellow at Imperial College London. His expertise spans AI in healthcare, metabolic surgery, and ancient history. He pioneered STARD-AI and QUADAS-AI guidelines for AI diagnostics, collaborated on AI-driven breast cancer screening with Google and NHS, and led global health policy initiatives. Ashrafian’s work bridges medicine, history, and philosophy, including his contributions to understanding historical figures’ medical conditions, such as King Tutankhamun’s epilepsy. He has authored over 550 publications, 12 books, and holds a PhD in computational physiology and an MBA with distinction. Awards include the Hunterian Prize and Wellcome Trust Fellowship. His research also explores AI ethics, quantum physics paradoxes, and art-based medical diagnostics. Education: PhD in Computational Physiology (Imperial College London) MBA (Warwick Business School) MD (University College London) Bachelor of Science in Immunology (University College London) Research Interests: Ashrafian’s work spans: AI in Medicine: Diagnostic algorithms, guideline development (STARD-AI/QUADAS-AI), and ethical frameworks. Metabolic Surgery: Bariatric interventions, gut microbiome, and obesity treatments. Ancient History: Medical analyses of historical figures (e.g., Tutankhamun, Julius Caesar) and art-based pathology identification. Philosophy: AI rights (AIONAI law), temporal paradoxes, and the Simulation Argument. Awards: Royal College of Surgeons Arris and Gale Lectureship Hunterian Prize Wellcome Trust Research Fellowship Advising & Innovation: Supervised >50 PhD students, co-founded Oxford Medical Products (weight loss tech), and serves as CSO at Flagship Pioneering’s Preemptive Health division. He advises on NHS digital transformation and global health policy. Labs/Teams: Leads AI initiatives at Imperial’s Institute of Global Health Innovation and collaborates with Google, NICE, and international institutions on health tech solutions.

Joshua D. Angristمشاهده پروفایل

استاد

• Econometrics
• Labor Economics
• Causal Inference
• +۳ مورد دیگر

Joshua D. Angrist is the Ford Professor of Economics at the Massachusetts Institute of Technology, where he has been a faculty member since 1996. He is also a co-founder and director of MIT's Blueprint Labs and a Research Associate at the National Bureau of Economic Research. Angrist shares the 2021 Nobel Prize in Economic Sciences with David Card and Guido Imbens for their methodological contributions to the analysis of causal relationships. Angrist received his B.A. from Oberlin College in 1982 and completed his Ph.D. in Economics at Princeton University in 1989. Prior to joining MIT, he taught at Harvard University and the Hebrew University of Jerusalem. His academic journey began somewhat unconventionally, as he left high school early after 11th grade, worked for over a year, and only later discovered his passion for economics through an inspiring teacher at Oberlin. Angrist's research focuses on developing and applying innovative econometric methods to answer important economic questions using natural experiments. His work spans labor economics, education economics, and causal inference methodology. He is particularly known for his contributions to instrumental variables methods and the Local Average Treatment Effect (LATE) framework developed with Guido Imbens. His research explores the economics of education and school reform, the impact of social programs on labor markets, and the effects of immigration and regulation. His recent publications reveal a continued focus on causal inference methods applied to education policy questions, labor market issues, and health economics. The trend shows increasing sophistication in research design, with particular attention to addressing selection bias and developing methods for external validity. His work spans theoretical econometric contributions alongside empirical applications in education, labor markets, and health. Sveriges Riksbank Prize in Economic Sciences in Memory of Alfred Nobel (2021) Fama Prize for Graduate Education (2018) Fellow of the American Academy of Arts and Sciences Fellow of the Econometric Society Angrist is deeply committed to teaching and mentoring. He has developed influential econometrics textbooks including 'Mostly Harmless Econometrics' and 'Mastering Metrics' with Jörn-Steffen Pischke. At MIT, he teaches courses including Labor Economics I (14.661), Econometric Data Science (14.32), and Labor Economics and Public Policy (14.64). He emphasizes selecting UROP students who have mastered foundational economics through courses like 14.64 and 14.32. Beyond MIT, Angrist co-founded Avela, a software startup using cutting-edge research to help schools improve enrollment and operations. Angrist co-founded and directs MIT's Blueprint Labs, which brings together researchers from economics, computer science, and education to develop innovative solutions for educational challenges. Through Blueprint Labs and Avela, his work bridges academic research with practical applications in education policy and technology.

• Environmental Health Engineering
• Wastewater-Based Epidemiology
• Bioremediation
• +۷ مورد دیگر

Rolf Halden is a Professor and Center Director at Arizona State University, holding appointments in the School of Sustainable Engineering and the Built Environment, the Biodesign Center for Environmental Health Engineering, and the Global Futures Scientists and Scholars program. He is a leading expert in environmental health engineering, wastewater-based epidemiology, and bioremediation. Education: Ph.D. in Civil (Environmental) Engineering, University of Minnesota (1997) M.S. in Civil (Environmental) Engineering, University of Minnesota (1994) M.S. in Biology, Technical University of Braunschweig, Germany (1992) Postdoctoral Fellow, Environmental Science, Lawrence Livermore National Laboratory (1998) Research Focus: Halden’s research integrates environmental chemistry, public health, and sustainability to understand how anthropogenic chemicals affect ecological and human health. His lab uses advanced mass spectrometry (LC-MS/MS, MALDI-TOF) to track pollutants such as PPCPs, microplastics, pesticides, and dioxins across air, water, soil, and biological systems. He pioneered the use of wastewater treatment plants as public health observatories, enabling real-time tracking of disease, drug use, and environmental exposures. Scientific Awards & Recognition: Leadership Award, Arizona State University (2018) Rocky Mountain Emmy Award (2018) Leroy E. Burney Lecturer, Johns Hopkins School of Public Health (2011) ACS Expert Program Member (2014–present) NIEHS Superfund R01 Working Group National Leader (2012–2014) Labs & Teams: Halden is the Founding Director of the Biodesign Center for Environmental Health Engineering at ASU, where he leads a multidisciplinary team focused on environmental proteomics, bioremediation, and diagnostic tool development. He also co-leads the Human Health Observatory , a national wastewater monitoring network. Grants & Funding: Halden has secured major funding from NSF, NIH, EPA, DoD, and private industry. Notable projects include the development of in-situ groundwater monitoring devices, national wastewater surveillance of SARS-CoV-2, and studies on microplastics and neurodegenerative disease.

Jimeng Sunمشاهده پروفایل

استاد

• Artificial Intelligence
• Healthcare Analytics
• Drug Discovery
• +۵ مورد دیگر

Dr. Jimeng Sun is a Health Innovation Professor at the Siebel School of Computing and Data Science and Carle Illinois College of Medicine at the University of Illinois Urbana-Champaign. Co-founder of Keiji AI , he leads groundbreaking research at the intersection of artificial intelligence and healthcare, actively deploying clinical AI systems and developing frameworks like PyHealth and Therapeutics Data Commons . His research spans four major areas: Clinical AI Systems : Developing interpretable models (e.g., RETAIN) for patient similarity, temporal event prediction, medication recommendation, and clinical outcome forecasting Drug Discovery : Creating molecular optimization frameworks, drug-target interaction models, and AI-driven platforms Clinical Trials : Pioneering patient-trial matching, outcome prediction, and optimization frameworks using deep learning and graph neural networks Biosignal Analysis : Advancing sleep staging, seizure classification, and automated EEG/Cardiac monitoring systems With over 500 top-tier publications (including in Nature , NEJM AI , and leading AI conferences) and an h-index of 99, his work has been recognized with the Top 100 AI Leaders in Drug Discovery and Advanced Healthcare award. He maintains active collaborations with institutions like Massachusetts General Hospital , Medidata Solutions , and OSF Healthcare . His recent publications reveal a strong focus on: Reinforcement learning applications in medical data analysis Large language model adaptation for clinical tasks Knowledge graph integration with AI systems Synthetic data generation for healthcare Multi-modal learning in clinical contexts Explainable AI for medical applications Dr. Sun's lab ( Sunlab ) emphasizes practical impact over theoretical work, actively collaborating with hospitals and healthtech companies. He welcomes contributions from clinicians, researchers, and industry partners through initiatives like his AI for Health webinar series .

Syed Hani Hassan Abidiمشاهده پروفایل

دانشیار

• Virology
• Immunology
• Viral Oncology
• +۷ مورد دیگر

Syed Hani Hassan Abidi is an Associate Professor at the Department of Biomedical Sciences , School of Medicine , Nazarbayev University , Kazakhstan. His research integrates virology , immunology , viral oncology , and bioinformatics , with a focus on HIV molecular epidemiology , viral evolution , and drug resistance . He has led international projects across Pakistan, Kenya, Afghanistan, and Kazakhstan, and is recognized for innovative teaching and MOOC development. Education: PhD in Virology and Immunology Research Interests: His laboratory employs bioinformatics (machine learning, AI), genomics , and proteomics to study HIV phylodynamics , viral co-infections , and oncogenic viruses like EBV in prostate cancer. He also explores microbiome-immunity interactions and designs antiviral drugs/vaccines . Recent Research Trends: His 2025 publications emphasize COVID-19 immunopathology , HIV/syphilis epidemiology in Pakistan , and particle physics contributions via ATLAS , showcasing interdisciplinary impact. Awards & Recognition: Outstanding Teachers Award (2019, Aga Khan University) Fellowship of Higher Education (UK, 2022) Teaching & Grants: He pioneered Pakistan’s first MOOC on Computer-Based Drug Discovery (2014) and received a 2022 SoTL grant for MOOC-based molecular biology education. His teaching integrates animations , films , and flipped classrooms . Collaborations & Labs: Leads projects on HIV drug resistance , HCV genomics in Kazakhstan , and AI-driven dementia diagnostics (Kazakh Brain Atlas). His lab collaborates with global institutions to advance viral disease surveillance and therapeutic innovation .

• Gynecologic Oncology
• Ovarian Cancer
• Breast Cancer
• +۵ مورد دیگر

Federica Tomao is an Associate Professor at the Department of Maternal, Child and Urological Sciences within Sapienza University of Rome. She actively teaches and supervises courses in Medicine and Surgery , Nursing , and Midwifery programs across multiple institutions. Current faculty member with academic rank Teaching roles in 6th, 3rd, and 2nd year courses Specialized in gynecologic oncology Research Focus : Her work spans ovarian cancer, breast cancer, and endometrial cancer, emphasizing chemotherapy optimization, precision medicine, and radiomics. Notably, she contributes to understanding PARP inhibitors, immune checkpoint therapies, and fertility preservation techniques in cancer survivors. Recent Publications highlight advancements in sarcopenia analysis, BRCA testing, and radiogenomic nomograms. These studies demonstrate her commitment to bridging imaging and molecular data for improved cancer management. Email : federica.tomao@uniroma1.it

Youngjae Youمشاهده پروفایل

استاد

• Antibody-Drug Conjugates
• Cancer Chemotherapy
• Medicinal Chemistry
• +۳ مورد دیگر

Youngjae You is a Professor of Empire Innovation in the Department of Pharmaceutical Sciences at the University at Buffalo School of Pharmacy. His research focuses on Antibody-Drug Conjugates, Cancer Chemotherapy, Medicinal Chemistry, and Targeted Drug Delivery. He holds adjunct roles at the University of Oklahoma Health Sciences Center and has led numerous grants totaling over $10 million in funding. Key awards include the 2019 Professor of Empire Innovation title and multiple DoD/CDMRP grants. His work emphasizes prodrug design, photodynamic therapy, and combination therapies. Education : PhD in Pharmaceutical Chemistry, Chungnam National University (2001) MS in Pharmaceutical Chemistry, Chungnam National University (2000) BPharm, Chungnam National University (1994) Research Interests : Dr. You specializes in developing light-activatable prodrugs for targeted cancer therapies, including far-red/NIR light-activated delivery systems. His work integrates quantitative pharmacokinetic modeling, singlet oxygen dynamics, and receptor-targeted drug conjugation to enhance therapeutic efficacy while minimizing off-target effects. Key applications include bladder, breast, and ovarian cancers. Funding Highlights : NIH/NIGMS: $1.37M (2023-2027) for light-responsive drug delivery National Cancer Institute: $2.1M (2022-2027) for bladder cancer treatments DoD/CDMRP/PRCRP: $392K (2017-2020) for photodynamic-chemotherapy combinations Awards : PHF Presidential Professorship (2018) American Cancer Society Research Scholar Grant (2013) Multiple DoD/CDMRP Idea Awards Service & Grants : Serves as Principal Investigator on 8 major grants. Active reviewer for Wellcome Trust, NIH, and international funding agencies. Holds patents on BODIPY derivatives and singlet oxygen-labile linkers. Lab & Collaborations : Leads the You Lab at UB, collaborating with bioengineers and clinicians to advance photomedicine and targeted drug delivery systems. Engaged in multidisciplinary teams addressing spatiotemporal control in cancer treatments.

Martin T. Wellsمشاهده پروفایل

استاد

• Applied Statistics
• Theoretical Statistics
• Bayesian Statistics
• +۷ مورد دیگر

Martin T. Wells is the Charles A. Alexander Professor of Statistical Sciences at Cornell University, with joint appointments in the Department of Statistical Science, Department of Biological Statistics and Computational Biology, Department of Social Statistics, and as Professor of Clinical Epidemiology and Health Services Research at Weill Medical School. He serves as Editor-in-Chief of the ASA-SIAM Book Series and Co-Editor of the Journal of Empirical Legal Studies. Cornell University, Ithaca, NY Weill Cornell Medical College Research Interests span applied and theoretical statistics, Bayesian methods, biostatistics, clinical epidemiology, and computational biology. His work bridges disciplines like finance, legal studies, and health services research. Article Trends highlight advancements in Bayesian modeling, quantum cognition machine learning, tensor analysis, and misclassification correction, with applications in genomics, finance, and public health. Fellow of the American Statistical Association Fellow of the Royal Statistical Society Contributions include developing statistical software (e.g., rTensor), methodological innovations in clinical trials, and empirical legal studies on civil rights and the death penalty.

Joel Gohمشاهده پروفایل

دانشیار

• Health services and systems
• Transportation, logistics and supply chains
• Operations research
• +۶ مورد دیگر

Joel Goh is Associate Professor at the Department of Analytics and Operations, NUS Business School, National University of Singapore. He serves as Director of the J.Y. Pillay Comparative Asia Research Centre (under NUS Global Asia Institute) and PhD Program Director at the Institute of Operations Research and Analytics (IORA). Previously, he was Assistant Professor at Harvard Business School (2014-2017) and Visiting Scholar (2017-2022). BSc, MSc, PhD in Operations, Information, and Technology from Stanford University His research focuses on healthcare analytics (preventing health conditions, hospital operations, frailty assessment), supply chain analytics (digital business models, platform leakage), and service platform operations (hospital-at-home programs, incentive design). He co-created the Robust Optimization Made Easy (ROME) software. Recent publications analyze workplace psychological safety (2024), hospital-at-home models (2024), and platform leakage dynamics (2023). His work spans 18+ journals with 740+ citations for burnout cost studies (2022) and 606+ citations for physician well-being research (2017). Teaching Honors : 2023: Best MBA Teaching & Skinner Innovation Award 2021: NUS Annual Teaching Excellence Award 2020: Early Career Research Excellence Award & 40 Under 40 Best MBA Professors Advising & Grants : Served as PhD Program Director. Received NUS Start-Up Grant R-314-000-110-133 (2021) and Humanities & Social Sciences Fellowship (2021). Editorial roles include Associate Editor at Management Science , Manufacturing & Service Operations Management , and Senior Editor at Production and Operations Management .

• Lymphoma
• Hodgkin Lymphoma
• Non-Hodgkin Lymphoma
• +۵ مورد دیگر

Jonathan W. Friedberg, M.D., M.M.Sc. is the Director of the Wilmot Cancer Institute and Professor in the Department of Medicine, Hematology/Oncology at the University of Rochester School of Medicine and Dentistry. He holds the Samuel E. Durand Chair in Medicine and leads one of the nation's premier lymphoma programs. Dr. Friedberg is internationally recognized for his expertise in lymphoma treatment, particularly in developing novel therapies and clinical trial approaches. Dr. Friedberg's research focuses on lymphoma, with particular expertise in Hodgkin lymphoma, non-Hodgkin lymphoma, Waldenstrom macroglobulinemia, and chronic lymphocytic leukemia. His work spans the entire treatment continuum from diagnosis through novel therapies including autologous stem cell transplantation and CAR-T cell interventions. He has built a comprehensive lymphoma program with expertise spanning hematopathology, radiation oncology, dermatology, and neurology, in addition to hematology and medical oncology. His research interests include developing risk-adapted treatment strategies, investigating novel therapeutic agents, and improving outcomes for patients with various lymphoma subtypes. Dr. Friedberg's extensive publication record demonstrates his leadership in lymphoma research, with recent work focusing on immunotherapy combinations, predictive modeling, risk stratification, and novel treatment approaches for various lymphoma subtypes. His research has significantly contributed to the understanding and treatment of lymphomas, particularly in developing more personalized and effective treatment strategies. Scientific Awards: Faculty Academic Mentoring Award (2012) Scholar in Clinical Research (2008) America's Top Doctors Selection (2008) Jacob Gitelman Award (2007) Lawrence A. Kohn Senior Teaching Fellow (2004-2006) Clinical Investigator Career Development Award (2003) Clinical Oncology Research Fellowship "Immunotherapy of Hodgkin's Disease" (2001-2003) Rising stars program for innovative research (2001-2003) As Director of the Wilmot Cancer Institute, Dr. Friedberg leads numerous clinical trials and research initiatives focused on advancing lymphoma treatment. He is actively involved in SWOG and has served in leadership roles for multiple clinical trials investigating novel therapies for lymphoma patients. His practice team includes Anna Morrison, R.N., and Kerri Hugelmaier, N.P., providing comprehensive care for lymphoma patients. Dr. Friedberg has established the Lymphoma Epidemiology of Outcomes (LEO) Consortium, a large observational cohort study supporting broad research on NHL prognosis and survivorship. His leadership extends to national organizations where he contributes to developing clinical practice guidelines and consensus recommendations for lymphoma treatment.

• RNA Biology
• Myeloid Malignancies
• Hematology
• +۴ مورد دیگر

Dr. Giulia Biancon is an Assistant Professor Adjunct in the Department of Medical Oncology and Hematology at Yale School of Medicine. She holds a PhD from the University of Milan (2019) and is a member of the Halene Lab, focusing on RNA biology and hematologic malignancies. Her research combines high-throughput methodologies to study RNA mechanisms in diseases like myeloid leukemias and splicing factor mutations. Education: PhD in Molecular Biology from the University of Milan (2019). Research Interests: RNA splicing, stress granules in cancer, epitranscriptomics, clonal hematopoiesis, and the interplay between genetic mutations and cellular pathways in blood cancers. Awards: 2024 Eclipse Award, 2022 ASH Abstract Achievement Award, and 2022 RNA Society Best Poster Award. Her work has been published in journals like Cell Reports , Blood , and Molecular Cell . Labs/Teams: Principal member of the Halene Lab and coordinator at the Yale Center for RNA Science and Medicine. Collaborates with institutions like the SeroNet network for immunology studies.

Andre Levchenkoمشاهده پروفایل

استاد

• Systems Biology
• Signal Transduction
• Cell Communication
• +۵ مورد دیگر

Andre Levchenko is the John C. Malone Professor of Biomedical Engineering at Yale University, with secondary appointments in the Department of Neurosurgery and affiliations with the Cancer Signaling Networks, Immunology, and the Yale Program in Neurodevelopment and Regeneration. His research focuses on systems biology, signal transduction, and cell-cell communication, utilizing microfluidics and computational modeling to study cancer progression, stem cell behavior, and neurological disorders. PhD, Columbia University MEng, Moscow Institute of Physics and Technology Levchenko's work explores how cells process dynamic signals to make critical decisions, particularly in glioblastoma migration, organoid development, and cardiovascular tissue engineering. His lab develops innovative microfluidic platforms and mathematical models to dissect multicellular communication and signaling networks. Recent publications highlight his contributions to understanding YAP-driven cancer invasion , NOTCH signaling in angiogenesis , and metabolic regulation of hypoxia responses . He has pioneered methods for organoid modeling and single-cell analysis , advancing precision in biological signaling studies. Scientific Awards : Computational Molecular Biology Post-Doctoral Fellowship (Burroughs Wellcome Fund) National Academies Keck Futures Conference Invitee Distinguished Guest Lecturer, University of Virginia American Asthma Foundation Early Excellence Award Fellow, American Institute for Medical and Biological Engineering Levchenko leads the Levchenko Lab at the Yale Systems Biology Institute, collaborating with institutions like Mayo Clinic and Yale Cancer Center. His research has received recognition in Faculty of 1000 and multiple journal highlights.

• Drug Delivery
• Nanomedicine
• Biopharmaceutics
• +۷ مورد دیگر

Dr. Shyh-Dar Li is a Professor and Tong Louie Chair in Pharmaceutical Sciences at the University of British Columbia's Faculty of Pharmaceutical Sciences, where he also serves as Chair of Nanomedicine and Chemical Biology. With a BSc in pharmacy from National Taiwan University (1998) and PhD in pharmaceutical sciences from UNC Chapel Hill (2008), followed by postdoctoral training at UC San Diego's Moores Cancer Center (2009), Dr. Li has established himself as a leading researcher in advanced drug delivery systems. His research focuses on developing innovative nanomedicine platforms for targeted delivery of biological therapeutics including peptides, proteins, antibodies, and nucleic acids. Dr. Li's laboratory has pioneered several novel drug delivery approaches, particularly in lipid-based nanoparticles, phospholipid-free vesicles, and polymer systems for cancer immunotherapy, pain management, and protein delivery. His work bridges fundamental nanotechnology with translational applications for difficult-to-treat diseases. Analysis of his recent publications reveals a strong emphasis on tumor microenvironment modulation, endosomal escape mechanisms for nucleic acid delivery, and non-invasive delivery routes for protein therapeutics. His research demonstrates increasing sophistication in nanocarrier engineering, with recent work incorporating machine learning approaches to optimize nanoparticle design and expanding into immunomodulatory therapies that harness the body's immune system to fight cancer. Scientific Recognition: 2014 AFPC New Investigator Award 2013 AAPS New Investigator Award in Pharmaceutics and Pharmaceutical Technologies 2013 CIHR New Investigator Award 2013 CSPS Early Career Award 2012 Prostate Cancer Foundation Young Investigator Award Dr. Li's research program has been consistently supported by major Canadian funding agencies including CIHR, NSERC, and MITACS. He actively collaborates across disciplines and accepts graduate students into his research program, focusing on cutting-edge approaches to overcome biological barriers in drug delivery. His laboratory, the Laboratory of Targeted Drug Delivery and Nanomedicine, serves as a hub for innovation in pharmaceutical nanotechnology.

Michael McAlpineمشاهده پروفایل

استاد

• 3D Printing
• Nanotechnology
• Biomedical Engineering
• +۴ مورد دیگر

Michael McAlpine is a Professor in the Mechanical Engineering department at the University of Minnesota . He also holds affiliations with the Biomedical Engineering and Electrical and Computer Engineering departments. His research focuses on 3D printing functional materials & devices , Nanoscale inks , Biomedical devices , Bioelectronics , and Flexible Microsystems . Research Interests : 3D Printing, Biomedical Engineering, Nanotechnology, Flexible Electronics, Microfluidics Labs : ME 361/363 Contact : mcalpine@umn.edu , (612) 626-3303, ME 117 Recent Research Trends include 3D Printed Biomedical Devices , Flexible Electronics , and Bioprinting Applications . His work spans from Spinal Organoid Formation to Programmable Drug Release Capsules . Scientific Award : Circulation Research 2020 Best Manuscript Award

Kristian Helinمشاهده پروفایل

استاد

• Cancer biology
• Epigenetics
• Stem cells
• +۵ مورد دیگر

Kristian Helin is Chief Executive and President of The Institute of Cancer Research (ICR), London, and a Professor with affiliations at the University of Copenhagen and Memorial Sloan Kettering Cancer Center. He founded/directed the Biotech Research & Innovation Centre (BRIC), Centre for Epigenetics, and Danish Stem Cell Center. His research focuses on epigenetic regulation, cancer biology, and stem cell differentiation. Education: Ph.D. Molecular Biology, University of Copenhagen (1991) M.Sc. Chemical Engineering, Technical University of Denmark (1988) Research Interests: Helin's work deciphers molecular mechanisms in cancer, emphasizing epigenetic drivers (e.g., H3K4/H3K36 methylation), transcriptional control, and therapeutic targeting. His lab identified E2F transcription factors, linked epigenetic dysregulation to leukemia/lymphoma, and develops drugs targeting kinases/epigenetic enzymes. Research spans acute myeloid leukemia, B-cell lymphoma, and solid tumors using CRISPR screens and preclinical models. Publication Trends: Recent articles (2023-2025) focus on epigenetic therapy, chromatin remodeling, and kinase signaling in cancer. Key themes include targeting NSD1/KDM5C/RIOK2 enzymes, combination therapies (EZH2/DOT1L inhibitors), and metabolic regulation in leukemia. Studies bridge basic mechanisms (enhancer regulation, insulator accessibility) with translational applications. Awards: Anders Jahre Prize (2014), ERC Advanced Grant (2011), Novo Nordisk Prize (2008) Memberships: Academia Europaea, Royal Danish Academy, EMBO Leadership: Helin co-founded EpiTherapeutics (acquired by Gilead) and leads the Epigenetics and Cancer lab at ICR. His team investigates AML pathogenesis and chromatin complexes like HUSH/NURF. Grants include ERC funding and innovation prizes.